Incyte raises lower end of 2024 sales forecast for blood disorder drug Jakafi
July 30 (Reuters) -Incyte Corp INCY.O on Tuesday raised the lower end of the annual sales forecast range for its blood disorder drug Jakafi, on the back of strong demand for the treatment, and also reported better-than-expected quarterly revenue of a newer drug.
Shares of the company rose 3.4% before the bell.
The company expects Jakafi sales in 2024 to be $2.71 billion at the lower end, compared with its earlier estimate of $2.69 billion, while keeping the upper end at $2.75 billion. Analysts on average expect the drug's sales for the period to be $2.70 billion, according to LSEG data.
Jakafi, used as a treatment for bone marrow related illnesses, is Incyte's top-selling drug. Sales from Jakafi were $706 million for the quarter ended June 30, above estimates of $676.9 million.
Total paid prescriptions for Jakafi increased 9% compared with a year earlier.
Opzelura is approved by U.S. health regulator to treat vitiligo and mild to moderate atopic dermatitis in patients 12 years of age and older. The drug's revenue rose 51.7% from a year earlier to $121.7 million, beating estimates of $112.5 million.
Delaware-based Incyte has been strengthening its dermatological pipeline with the help of Opzelura as the company braces for a loss of exclusivity related to its biggest drug Jakafi in 2028.
However, the company said it will discontinue further development of five cancer therapies as part of a strategic review.
The company's total revenue for the second quarter stood at $1.04 billion, above estimates of $1.03 billion.
On an adjusted basis, the U.S. drugmaker reported a loss of $1.82 per share in the second quarter, compared with a profit of 99 cents a year earlier, primarily due to expenses related to the $750 million acquisition of Escient Pharmaceuticals in May.
Reporting by Puyaan Singh in Bengaluru; Editing by Krishna Chandra Eluri
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
